March 12, 2018 / 11:47 AM / 8 months ago

Biogen to buy Pfizer's neurology drug in deal nearing $600 mln

March 12 (Reuters) - Biogen Inc said on Monday it would buy Pfizer Inc’s experimental treatment for cognitive impairment associated with schizophrenia in a deal whose value could near $600 million.

Biogen said it would pay Pfizer $75 million upfront, up to $515 million in development and commercialization milestone payments, as well as royalties. (Reporting by Tamara Mathias in Bengaluru; Editing by Savio D’Souza)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below